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Background: Gamma-glutamyl transpeptidase (GGT) is now considered to be one of the risk factors for
cardiovascular disease. However, whether statins can alter GGT levels in arterial atheromatous plaque has not yet
been studied. Therefore, the aim of this study is to determine whether statins can effectively decrease the
expression of GGT in arterial atheromatous plaques.
Methods: We randomly divided 45 apolipoprotein E–knockout (ApoE KO) male mice into three groups: normal diet
(ND) group,high-cholesterol diet (HCD) group and high-cholesterol diet and atorvastatin (HCD + Ato) group. We fed
high-cholesterol food to the HCD and HCD + Ato group. After eight weeks, atorvastatin 5 mg•kg−1•d−1 was given to
HCD + Ato group mice. The serum GGT-1, intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell-adhesion
molecule-1 (VCAM-1) levels were measured at end of 16 weeks by using ELISA methods. The expressions of GGT-1,
ICAM-1 and VCAM-1 in aorta were measured by RT-PCR and Western Blot.
Results: The ApoE KO mice with HCD were associated with a marked increase in plasma lipid, inflammatory factors,
GGT-1, ICAM-1 and VCAM-1. The expressions of GGT-1, ICAM-1 and VCAM-1 in HCD aortic tissue were increased. At
the HCD + Ato group were treated with atorvastatin, the levels of lipid, GGT-1, ICAM-1 and VCAM-1were suppressed.
Meanwhile, the expressions of GGT-1, ICAM-1 and VCAM-1 were significantly decreased in the whole aorta plaques.
Conclusions: The effect of statins on the expression of GGT in aorta plaque was firstly observed in animal model.
The research shows that statins can significantly decrease the expression of GGT in aortic atherosclerotic plaques.
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In clinical practice statins can be used to decrease low-
density lipoprotein (LDL) levels. Cardiovascular events
and mortality are decreased significantly by the use of
statins [1-3], and statins have already become a standard
treatment for coronary heart disease. The mechanisms
by which statins may alleviate the symptoms of coronary
artery disease may not be limited only to their lipid-
lowering effect. Statins also have pleiotropic biological* Correspondence: marty007@163.com; zhongzt2007@163.com
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unless otherwise stated.effects that occur before lipid levels decrease. These add-
itional effects may be related to the ability of statins to
improve the bioavailability of nitric oxide [4], repair dam-
aged cells [5], promote angiogenesis [6], and function as
an anti-inflammatory mediator and antioxidant [7].
However, the occurrence of cardiovascular events in
clinical practice cannot be prevented. This is despite
being able to control LDL levels, the main risk factor.
Research has shown that when the LDL levels are de-
creased to 2–3 mmol/L after intensive treatment with
statins, the risk of cardiovascular events is decreased by
40%–50% [8]. This means that a considerable risk has
not been effectively controlled. Residual cardiovascular
risk remains that is not managed effectively. Thishis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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independent of the presence of high lipid levels. The
non-lipid associated risk is considered to mainly be in-
fluenced by the levels of uric acid, fibrinogen, C-reactive
protein (CRP) and homocysteine [9].
Gamma-glutamyl transpeptidase (GGT) is now consid-
ered to be one of the risk factors for cardiovascular
disease [10-12]. GGT is the critical enzyme in the
gamma-glutamyl cycle. The primary function of GGT is
to hydrolyze glutathione, which is a main in vivo antioxi-
dant. Therefore, many studies consider GGT level as
anindex of the oxidation state [10,13,14]. Serum GGT
levels are correlated with multiple risk factors in cardio-
vascular disease. Furthermore, serum GGT levels can
predict the prognosis of cardiovascular diseases and car-
diovascular events. A few studies [15] have shown that
GGT, located in arterial atheromatous plaques, can pro-
mote the oxidation of LDL through a redox reaction and
lead to the further development of plaque. Furthermore,
whether statins can alter GGT levels in arterial ather-
omatous plaque has not yet been studied. Therefore, the
aim of this study is to determine whether statins can ef-
fectively decrease the expression of GGT in arterial




This study was approved by the Experimental Animal
Ethics Committee of Wuhan General Hospital. Forty-
five apolipoprotein E–knockout (ApoE KO) male mice
(C57BL/6 J, 6 weeks old, weighing an average of 20.5 g)
were bred from breeding pairs obtained from The
Jackson Laboratory (Bar Harbor, Maine, USA) by the
Animal Center of Peking University. One week after
adaptive feeding in a specific pathogen free vivarium, the
experimental protocol was initiated. Thirty mice were
randomly selected and fed a high cholesterol diet (HCD)
that contained 1.25% cholesterin, 10% coconut oil and
basic diet. After 8 weeks, the mice in the HCD group
were further randomly divided into two groups: 15 mice
remained on a high cholesterol diet alone (HCD group)
and 15 mice were treated with atorvastatin (HCD and
Ato group). The mice in the HCD group were continued
on a high cholesterol diet and gavaged with 10 mL/(kg•d)
of 0.5% sodium carboxymethyl cellulose (CMC-Na) solu-
tion each day. According to the body surface area (BSA)
normalization method [16], we converted the drug dose
between mice and humans. A dose of 5 mg•kg−1•d−1 in
mice is equivalent to a daily dose of about 25 mg atorva-
statin in an adult human subject. The HCD and Ato
group were given 5 mg•kg−1•d−1 atorvastatin dissolved in
0.5% CMC-Na bygavage for 8 weeks. An additional 15
mice were given normal chow for 16 weeks and werereferred to as the normal diet group (ND group). All the
mice were weighed once a week and the dose of atorva-
statin and vehicle adjusted accordingly. After 16 weeks, all
of the mice were fasted, anesthetized with 0.5 ~ 1.0 mL of
1% pentobarbital (i.p.) and retinal tissue and blood were
collected. The blood was centrifuged at 3000 rpmfor
10 min. The plasma was stored at −80°C. Mice were eu-
thanized and the aortic root of the aortic arch vessels was
collected.
Biochemical measurements
Blood samples were collected from the jugular vein.
Blood lipid analysis was performed before and after
8 weeks on the high-cholesterol diet and after 8 weeks
of atorvastatin treatment. Plasma totalcholesterol (TC),
LDL and total triglyceride (TG) concentrations were
measured by an enzymatic method (BioMerieux, Lyon,
France) using an automated analyzer (Type 7170A,
Hitachi, Japan). Enzyme-linked immunosorbent assay
(ELISA) kits were used to measure plasma levels of
GGT-1 (Cloud-Clone Crop, USA), intercellular cell ad-
hesion molecule-1 (ICAM-1, RayBiotech, USA), vascular
cell-adhesion molecule-1 (VCAM-1, Fitzgerald, USA),
interleukin-6 (IL-6, R&D Systems Inc., USA) and high-
sensitivity C-reactive protein (hs-CRP, BioVendor R&D
Systems Inc., CZ).
Quantitative detectionof mRNA levels by real time
polymerase chain reaction
The whole aorta was milled into a powder in liquid ni-
trogen and suspended in 1 mLof Trizol. Total RNA was
extracted according to the manufacturer’s instructions.
cDNA was reverse transcribed with reverse transcrip-
taseand amplified using the real time polymerase chain
reaction (RT-PCR). The glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) gene served as the internal ref-
erence. The tested gene and GAPDH primers were de-
signed using Primer 5.0 software (Premier Bio, CA) and
synthesized using Taq polymerase and reagents from
Invitrogen. The primer sequences were: GGT-1: forward,
5′-GGACGTGACCAAGGTGATCT-3′; reverse, 5′-TCG
TCCATCTCGTCATTGAA-3′; VCAM-1: forward, 5′-GT
GCATCCCCAACATTCTCT-3′; reverse, 5′-TGGTTCTC
CAACCTCCAAAG-3′; ICAM-1: forward, 5′-TTGAAC
AGTGACAGCCCTTG-3′; reverse, 5′-CTCCGTGGGAA
TGAGACACT-3′; GAPDH: forward, 5′-GCCCTCAAT
GACCTTTGT-3′; reverse, 5′-AAACTGTGAAGAGGGG
CAGA-3′. The reaction conditions were: initial denatur-
ation step for 3 min at 94°C, denature at 94°C for 30s,
anneal 30s at 58°C, elongation 30s at 72°C for 30 cycles.
A final, elongation step at 72°C for 8 min was included
to complete the synthesis of reaction products. Reaction
products were separated on a 1% agarose electrophor-
esis gel and observed under UV light. Samples were
Table 1 The influences of atorvastatin on blood lipid,
hs-CRP and IL-6
Time ND HCD HCD + Ato
TC(mmo/L) 0 W 1.51 ± 0.24 1.42 ± 0.34 1.32 ± 0.28
8 W 1.53 ± 0.17 22.31 ± 1.96* 23.08 ± 1.77*
16 W 1.49 ± 0.09 26.58 ± 2.08* 20.01 ± 1.16#
TG(mmo/L) 0 W 1.07 ± 0.51 0.99 ± 1.04 1.11 ± 0.08
8 W 1.03 ± 0.45 1.24 ± 1.29 1.31 ± 0.78
16 W 1.05 ± 0.59 1.44 ± 1.28 1.38 ± 0.56
LDL(mmo/L) 0 W 0.97 ± 0.14 1.06 ± 0.27 1.01 ± 0.03
8 W 1.05 ± 0.08 15.33 ± 1.17* 15.88 ± 2.34*
16 W 0.98 ± 0.33 16.87 ± 1.24* 9.53 ± 1.87#
hs-CRP(mg/ml) 0 W 2.34 ± 0.13 2.29 ± 0.14 2.33 ± 0.13
8 W 2.41 ± 0.15 6.58 ± 1.72* 6.71 ± 1.68*
16 W 2.39 ± 0.15 11.83 ± 2.09* 7.75 ± 1.87#
IL-6(ng/ml) 0 W 0.17 ± 0.05 0.16 ± 0.04 0.17 ± 0.05
8 W 0.18 ± 0.05 0.32 ± 0.15* 0.34 ± 0.14*
16 W 0.17 ± 0.06 0.57 ± 0.21* 0.13 ± 0.08#
Apolipoprotein E–knockout mice were treated with ND, HCD, or HCD plus
atorvastatin, as described in the Methods section.TC: total cholesterol; TG: total
triglyceride; LDL: low-density lipoprotein; HDL: high-density lipoprotein;
hs-CRP: high-sensitivity C-reactive protein; IL-6: interleukin-6. ND: normal
standard diet; HCD: high-cholesterol diet; Ato: atorvastatin, at 5 mg•kg−1•d−1.
Values are means ± SD, n =15 for each group. *:P < 0.01 compared with ND
group; #:P < 0.05 compared with HCD group.
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7500 Real-Time PCR System. Target gene mRNA levels
were calculated and normalized to GAPDH mRNA.
Western blot determination
Aortic tissue (0.1 g) was homogenized in lysis buffer on
an ice-bath until the tissue was completely uniform. The
lysate was centrifuged at 9 kr/min for 10 min at 4°C and
the supernatant collected. The total protein concentra-
tion was measured by the bicinchoninic acid method.
Forty microgramsof total protein was added to 2 × SDS
buffer solution and denatured by heating at 100°C for
3 min. Proteins were separated by electrophoresis onan
8% SDS-polyacrylamide gel. The total loading quantity
of the protein samples was 40 μg per well. Proteins were
transferred to nitrocellulose membrane by electroblot-
ting and stained with ponceau to observe the transfer
effects and determine the location of the protein mo-
lecular weight standards. The membrane was then
blocked for 2 h at 37°C with 5% skim milk powder be-
fore adding the primary antibody and incubating at 4°C
overnight. The primary antibody concentrations were
as follows: mouse polyclonal anti-GGT-1 (1:1000 dilu-
tion, Santa Cruz, USA), goat polyclonal anti-VCAM-1
(1:1000, R&D Systems), polyclonal anti-ICAM-1 (1:1000
dilution, Santa Cruz, USA). After incubating with the
primary antibody the membranes were washed three
times in TBST buffer solution. Horseradish Peroxidase
(HRP) was added to goat anti-rabbit secondary antibody
(1:5000 dilution, Pierce Chemical, USA) with a concen-
tration of 1:3000 to conjugate with HRP at 37°C for 1 h.
Membranes were washed an additional three times with
TBST buffer solution and developed by X-ray. Alpha
Imager HP (Alpha Innotech, USA) gel imaging appar-
atus was used to acquire images. The results were ana-
lyzed with an Alpha Ease Fc (Alpha Imager 3400) image
acquisition and analysis system (Alpha Innotech, USA).
The target proteinsare expressed as the ratio of the inte-
grated density of the target gene and the GADPH band.
Statistics
SPSS version 18.0 (SPSS Inc, Chicago, Illinois) statistical
software was used for statistical analysis. Comparisons
were performed by Student’s t test and ANOVA followed
by the Student–Newman–Keuls test. Categorical variables
were analyzed using the chi-squared test. Pearson’s correl-
ation analysis was used to examine the correlation between
serum GGT-1 and inflammatory factors, hs-CRP and IL-
6. A P value less than 0.05 was considered significant.
Results
Atorvastatin reduced blood lipid, hs-CRP and IL-6
There were no significant differences in plasma lipid, hs-
CRP and IL-6 levels among the three groups at baseline.After 8 weeks of a high-cholesterol diet, plasma concen-
trations of TC, LDL, hs-CRP and IL-6 were significantly
increased (P < 0.01). Plasma TG concentrations were not
different. After the ApoE KO mice were treated with
atorvastatin, the level of TC, LDL, hs-CRP and IL-6 in
the HCD and Ato group decreased significantly com-
pared with the HCD group (P < 0.05, Table 1).
ELISA and RT-PCR analysis of GGT-1, VCAM-1 and ICAM-1
The plasma concentrations of GGT-1, VCAM-1 and
ICAM-1 detected by ELISA in the HCD and Ato group
decreased significantly compared with the HCD group
(P < 0.001) (Figure 1). Plasma GGT-1 levels had a weak
correlation with the level of hs-CRP (r = 0.341, P < 0.001)
and IL-6 (r = 0.278, P < 0.001).
Real-time quantitative PCR showed that the expres-
sion of GGT-1, VCAM-1, and ICAM-1 increased signifi-
cantly compared with the ND group (ND group versus
HCD group: GGT-1, 1 ± 0.13 versus 4.44 ± 0.84, P < 0.01;
VCAM-1, 1 ± 0.18 versus 17.07 ± 1.27, P < 0.01; ICAM-1,
1 ± 0.19 versus 20.51 ± 2.07, P < 0.01). However, the ex-
pression of GGT-1, VCAM-1, and ICAM-1 decreased sig-
nificantly in the HCD and Ato group compared with the
HCD group (HCD group versus HCD and Ato group,
GGT1, 4.44 ± 0.84 versus 1.96 ± 0.39, P < 0.01; VCAM-1,
17.07 ± 1.27 versus 2.51 ± 0.53, P < 0.01; ICAM-1, 20.51 ±
2.07 versus 2.71 ± 0.43, P < 0.01).
Figure 1 ELISA and RT-PCR analysis of GGT-1, VCAM-1 and ICAM-1. A: effect of atorvastatin on GGT-1, VCAM-1and ICAM-1 serum
concentrations in ApoE KO mice. Serum GGT-1, VCAM-1and ICAM-1 was measured using an ELISA kit. *P <0.01 as compared with ND group;
#P <0.01 as compared with HCD group. B: effect of atorvastatin treatment on GGT-1, VCAM-1 and ICAM-1 mRNA expression in arterial
atheromatous plaque. The mRNA levels of GGT-1, VCAM-1 and ICAM-1were measured by RT-PCR, as described in the Methods section. *P <0.01
as compared with ND group; #P <0.01 as compared with HCD group.
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The Western blots showed that the expressing levels of
GGT-1, VCAM-1 and ICAM-1 inwhole aortic tissue-
from ApoE KO mice decreased sharply compared with
the HCD group after 8 weeks of atorvastatin treatment
(Figure 2).Figure 2 The protein levels of GGT-1, VCAM-1 and ICAM-1 were meas
A: densitometric measurements of GGT-1, VCAM-1 and ICAM-1 from Weste
VCAM-1 and ICAM-1 was shown.Discussion
Atherosclerosis is a complex, progressive disease result-
ing from the combined effect of several factors. GGT is
the key enzyme to hydrolyze glutathione, amain in vivo
antioxidant. In our study, the effect of atorvastatin on
the expression of GGT in arterial atheromatous plaquesured by Western blots, as described in the Methods section.
rn blots. B: one representative result of Western blots of GGT-1,
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show that atorvastatin can, simultaneously, decrease the
expression of adhesion molecules, VCAM-1 and ICAM-
1, in aortic tissue.
Glutathione was hydrolyzed by GGT and resulted in
many oxidized substances, such as reactive oxygen spe-
cies (ROS), oxidizedlow-density lipoprotein (Ox-LDL)
and so on [17]. At present, many studies have confirmed
that GGT level is an independent risk factor for cardio-
vascular disease, and it can predict the prognosis of pa-
tients with cardiovascular diseases and the occurrence of
cardiovascular events [11,18,19]. The evidence, that the
GGT activity is increased in arterial atheromatous pla-
ques [20], suggests that GGT has the possibility to pro-
mote the developmentof arterial atheromatous plaque.
Some studies have indicated that the GGT activity in pa-
tients with acute coronary syndrome (ACS) was higher
than patients with stable coronary artery disease (CAD)
[21]. There is also a positive correlation between GGT
and the SYNTAX score, which reflects the complexity
and severity of the coronary arterylesion [22].
After GGT accumulates in a plaque, the formation of
Ox-LDL [17] and inflammation [23] are promoted by an
increase in oxidative stress, which contributes to apop-
tosis, plaque rupture, and the progression and instability
of the atherosclerotic plaque. In our study, atorvastatin
can significantly decrease the expression of GGT in aor-
tic atherosclerotic plaques. There are several potential
mechanisms.
1. Atorvastatin could reduce the interaction of LDL
with GGT,and block serum GGT transfer into the
atheromatous plaque by decreasing LDL levels in
blood. Studies have shown that LDL can be
transported with GGT and catalyze activity within
plaques [24]. If the level of LDL is reduced, the
transport of GGT in the blood into the plaque and
the expression of GGT will also be reduced. Our
research has found that by decreasing LDL levels in
the blood of experimental animals, the expression
level of GGT in the plaque decreases significantly at
the same time.
2. GGT could be a marker of an increased oxidation
state [10,13,14]. Atorvastatin could decrease the
expression of GGT by reducing inflammatory factors
and oxidative stress. CRP and IL-6 are indices that
reflect the conditionof atherosclerotic inflammation.
Many studies have found that there is a positive
correlation between serum GGT levels, CRP and
IL-6 [25,26]. GGT is the main enzyme that could
catalyze the metabolism of the thiol antioxidant
GSH. Thus, its level might also reflect the degree of
inflammation and oxidative stress. When the mice in
our experiment were fed with atorvastatin, the levelsof GGT, CRP and IL-6 in serum were simultaneously
decreased.
3. The expression of VCAM-1 and ICAM-1 were
decreased by atorvastatin. Monocytes that adhered
to the arterial intima and foam cells decreased.
Finally, the accumulation of plaque in the local tissue
was decreased. Aldo Paolicchi et al. [15] found
mainly CD68+ foam cells in the atheromatous
plaque,which had GGT catalytic activity. Monocytes
in the blood were the main source of foam cells [27].
VCAM and ICAM mediate monocyte attachment to
endothelial cells and the arterial wall [28]. This is a
critical step in the process of atherosclerosis.
Previous studies have also shown that statins can
inhibit the expression of VCAM and ICAM in
endothelial cells [29,30]. Therefore, atorvastatin may
first inhibit the expression of VCAM and ICAM in
endothelial cells that results in decreased monocyte
attachment to endothelial cells. Finally, the
formation of foam cells and the accumulation of
plaque in the local tissue decreased. In our study,
the mRNA and protein expression levels of VCAM,
ICAM and GGT in thewhole aortic tissue decreased
significantly (P < 0.01). This shows that atorvastatin
can decrease the content of GGT in the plaque
through VCAM and ICAM.
We found that feeding a high fat diet can induce the
expression of GGT in atheromatous plaques of ApoE
KO mice. There are different mechanisms for atheroma-
tous to inhibit the expression of GGT in plaques. Statins
can inhibit the expression of GGT in atheromatous
plaque of local tissue, which leads to a decrease in oxida-
tive stress in the plaque. This may promote the
stabilization of atherosclerotic plaque and reduce the in-
cidence of cardiovascular events. The results of this
study revealed yet another new way for statins to act on
plaques.Conclusion
In our study, the effect of statins on the expression of
GGT in arterial atheromatous plaque was first observed
in an animal model. Our findings show that statins can
significantly decrease the expression of GGT in aortic
atherosclerotic plaques.Abbreviations
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